The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is a huge mover today! About 164,577 shares traded hands. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has risen 35.75% since April 18, 2016 and is uptrending. It has outperformed by 31.32% the S&P500.
The move comes after 6 months positive chart setup for the $716.97M company. It was reported on Nov, 18 by Barchart.com. We have $25.15 PT which if reached, will make NASDAQ:SCMP worth $401.50 million more.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage
Out of 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Sucampo Pharma has been the topic of 21 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Mizuho maintained the shares of SCMP in a report on Friday, November 13 with “Neutral” rating. The firm has “Buy” rating given on Tuesday, November 15 by Maxim Group. Northland Capital initiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Wednesday, September 7 with “Outperform” rating. The rating was maintained by WallachBeth Capital with “Hold” on Thursday, August 27. UBS initiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Tuesday, February 9. UBS has “Buy” rating and $20 price target. Mizuho upgraded the stock to “Buy” rating in Wednesday, April 20 report. Maxim Group maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Wednesday, August 26. Maxim Group has “Buy” rating and $25 price target. The firm has “Neutral” rating by Mizuho given on Friday, January 15. Jefferies initiated the stock with “Hold” rating in Friday, November 20 report. The stock has “Neutral” rating given by Mizuho on Monday, January 18.
According to Zacks Investment Research, “Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.”
Insitutional Activity: The institutional sentiment is 0.98 in 2016 Q2. Its the same as in 2016Q1. The ratio has no change, as 17 funds sold all Sucampo Pharmaceuticals, Inc. shares owned while 46 reduced positions. only 22 funds bought stakes while 40 increased positions. They now own 17.83 million shares or 12.41% less from 20.36 million shares in 2016Q1.
Secor Advsr Ltd Partnership accumulated 0.09% or 68,688 shares. Dupont Mngmt reported 130,758 shares or 0.03% of all its holdings. Wells Fargo Mn has invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Ubs Asset Management Americas last reported 0% of its portfolio in the stock. Blackrock Investment Mngmt Ltd Llc has 0% invested in the company for 92,447 shares. Manufacturers Life Insurance The has invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Gsa Cap Prtn Llp holds 82,540 shares or 0.05% of its portfolio. D E Shaw And Com owns 26,647 shares or 0% of their US portfolio. Blackrock Fund accumulated 1.20M shares or 0% of the stock. Barclays Public Ltd Company accumulated 0% or 600 shares. Moreover, Menta Limited Liability Corp has 0.27% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 178,582 shares. Millennium Management Llc holds 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 426,527 shares. Renaissance Tech Limited Liability has 1.11M shares for 0.02% of their US portfolio. The New York-based Metropolitan Life Ny has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Natl Bank Of Montreal Can owns 25,285 shares or 0% of their US portfolio.
Insider Transactions: Since November 15, 2016, the stock had 0 buys, and 1 insider sale for $27,514 net activity. The insider Smith Andrew P sold 1,766 shares worth $27,514.
More news for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) were recently published by: Moodys.com, which released: “Moody’s assigns B3 CFR to Sucampo Pharmaceuticals” on October 01, 2015. Bizjournals.com‘s article titled: “Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million” and published on January 11, 2016 is yet another important article.
SCMP Company Profile
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a biopharmaceutical company. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. The Firm operates through development and commercialization of pharmaceutical products segment. The Company’s activities are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts activities in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.